Cogent Biosciences, Inc. (COGT)Healthcare | Biotechnology | Waltham, United States | NasdaqGS
34.67 USD
-2.42
(-6.525%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 34.59 -0.08 (-0.084%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:15 a.m. EDT
Cogent Biosciences presents a classic biotech dilemma: exceptional balance sheet strength masking severe fundamental deterioration. The company holds a fortress-like liquidity position with a massive cash reserve relative to debt and a negligible short float, suggesting management is well-capitalized to pursue its pipeline. However, the business itself is currently failing to generate value, evidenced by deep losses in both assets and equity, negative free cash flow, and a trailing P/E that is mathematically undefined due to negative earnings. The stock has suffered a catastrophic multi-year decline, dropping nearly 80% over the last seven years, which serves as a stark warning that the market does not believe the current pipeline can yet deliver commercial success. Despite a 'strong buy' analyst recommendation driven by potential future upside, the lack of a dividend and the absence of recent positive annual returns suggest the investment thesis remains unproven. Options activity confirms this skepticism, with traders aggressively buying downside protection while waiting for a binary event to drive the price higher. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.095916 |
| AutoETS | 0.096599 |
| AutoARIMA | 0.097018 |
| AutoTheta | 0.121465 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 2.97 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.105 |
| Excess Kurtosis | -1.00 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 45.88 |
| Market Cap | 6,016,110,592 |
| Forward P/E | -31.28 |
| Beta | 0.33 |
| Previous Name | Unum Therapeutics Inc. |
| Website | https://www.cogentbio.com |
As of Aug. 22, 2026, 4:15 a.m. EDT: Speculators are positioning defensively with heavy put volume relative to calls, particularly in the near term where out-of-the-money puts show significant open interest. While there is some call volume at strikes significantly above the current price (indicating a speculative hope for a catalyst-driven rally), the dominant flow is hedging or betting against a continued decline, with implied volatility remaining elevated on downside protection.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.0703642 |
| Address1 | 275 Wyman Street |
| Address2 | 3rd Floor |
| All Time High | 70.64 |
| All Time Low | 1.18 |
| Ask | 44.2 |
| Ask Size | 5 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,499,190 |
| Average Daily Volume3 Month | 2,411,269 |
| Average Volume | 2,419,800 |
| Average Volume10Days | 1,499,190 |
| Beta | 0.329 |
| Bid | 33.5 |
| Bid Size | 3 |
| Board Risk | 6 |
| Book Value | 2.724 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 34.67 |
| Current Ratio | 13.573 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 36.845 |
| Day Low | 34.53 |
| Debt To Equity | 45.88 |
| Display Name | Cogent Biosciences |
| Dividend Date | 1,604,880,000 |
| Earnings Timestamp | 1,786,365,000 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | -386,456,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -14.321 |
| Enterprise Value | 5,534,348,288 |
| Eps Current Year | -2.2143 |
| Eps Forward | -1.10821 |
| Eps Trailing Twelve Months | -2.16 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 38.6352 |
| Fifty Day Average Change | -3.9652023 |
| Fifty Day Average Change Percent | -0.10263186 |
| Fifty Two Week Change Percent | 209.08334 |
| Fifty Two Week High | 43.73 |
| Fifty Two Week High Change | -9.060001 |
| Fifty Two Week High Change Percent | -0.20718046 |
| Fifty Two Week Low | 11.6 |
| Fifty Two Week Low Change | 23.069998 |
| Fifty Two Week Low Change Percent | 1.9887929 |
| Fifty Two Week Range | 11.6 - 43.73 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,522,330,200,000 |
| Float Shares | 172,560,477 |
| Forward Eps | -1.10821 |
| Forward P E | -31.284683 |
| Free Cashflow | -186,149,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 258 |
| Fullday Change | -2.42 |
| Fullday Change Percent | -6.52468 |
| Fullday Price | 34.5861 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00424 |
| Held Percent Institutions | 1.1497799 |
| Implied Shares Outstanding | 173,524,982 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,604,880,000 |
| Last Split Factor | 1:4 |
| Long Business Summary | Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts. |
| Long Name | Cogent Biosciences, Inc. |
| Market | us_market |
| Market Cap | 6,016,110,592 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_675599465 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -377,179,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,434,306,332 |
| Number Of Analyst Opinions | 11 |
| Open | 36.66 |
| Operating Cashflow | -307,544,992 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 617 945 5576 |
| Post Market Change | -0.08389664 |
| Post Market Change Percent | -0.24198627 |
| Post Market Price | 34.5861 |
| Post Market Time | 1,787,959,805 |
| Prev Name | Unum Therapeutics Inc. |
| Previous Close | 37.09 |
| Price Eps Current Year | -15.657318 |
| Price Hint | 2 |
| Price To Book | 12.727606 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.362 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -2.42 |
| Regular Market Change Percent | -6.52468 |
| Regular Market Day High | 36.845 |
| Regular Market Day Low | 34.53 |
| Regular Market Day Range | 34.53 - 36.845 |
| Regular Market Open | 36.66 |
| Regular Market Previous Close | 37.09 |
| Regular Market Price | 34.67 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,771,022 |
| Return On Assets | -0.43842 |
| Return On Equity | -1.09737 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 173,524,982 |
| Shares Percent Shares Out | 0.10609999 |
| Shares Short | 18,411,111 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 16,557,226 |
| Short Name | Cogent Biosciences, Inc. |
| Short Percent Of Float | 0.1067 |
| Short Ratio | 9.61 |
| Source Interval | 15 |
| State | MA |
| Symbol | COGT |
| Target High Price | 62.0 |
| Target Low Price | 45.0 |
| Target Mean Price | 55.81818 |
| Target Median Price | 55.0 |
| Total Cash | 792,300,032 |
| Total Cash Per Share | 4.565 |
| Total Debt | 244,260,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.16 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 36.92465 |
| Two Hundred Day Average Change | -2.25465 |
| Two Hundred Day Average Change Percent | -0.061060842 |
| Type Disp | Equity |
| Volume | 1,771,022 |
| Website | https://www.cogentbio.com |
| Zip | 2,451 |